Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals Inc., the leader in development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced the presentation of clinical data of the Company’s lead candidate, ACY-1215, for the treatment of relapsed or refractory multiple myeloma at the 18th Congress of the European Hematology Association (EHA), on June 15th, 2013, in Stockholm, Sweden. ACY-1215 is an oral, selective HDAC6 inhibitor currently being evaluated in a Phase 1b clinical trial in combination with the best-in-class drug Revlimid® (lenalidomide, Celgene) and a Phase 1/2 clinical trial in combination with the first-in-class drug Velcade® (bortezomib, Takeda Millennium) for the treatment of relapsed or refractory multiple myeloma.
Help employers find you! Check out all the jobs and post your resume.
BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals Inc., the leader in development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced the presentation of clinical data of the Company’s lead candidate, ACY-1215, for the treatment of relapsed or refractory multiple myeloma at the 18th Congress of the European Hematology Association (EHA), on June 15th, 2013, in Stockholm, Sweden. ACY-1215 is an oral, selective HDAC6 inhibitor currently being evaluated in a Phase 1b clinical trial in combination with the best-in-class drug Revlimid® (lenalidomide, Celgene) and a Phase 1/2 clinical trial in combination with the first-in-class drug Velcade® (bortezomib, Takeda Millennium) for the treatment of relapsed or refractory multiple myeloma.
Help employers find you! Check out all the jobs and post your resume.
